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Background: Neonatal lesion in the ventral hippocampus (NLVH) is a validated animal model to study
schizophrenia from a neurodevelopmental perspective. This animal model is also used to investigate how neonatal
lesions may alter the genetic expression of dopaminergic receptors. The present study compares mRNA expression
levels of dopamine receptors (drd2 and drd3) in lymphocytes and brain of NLVH animals at two different age
stages: young and adult.
Methods: The NLVH procedure was performed on 20 male Wistar rats at postnatal days 5–7. The mRNA expression
levels of drd2 and drd3 genes in lymphocytes, nucleus accumbens, hippocampus and prefrontal cortex were
measured and analyzed at postnatal days 45 and 90. The results were compared and contrasted with respective
sham groups.
Results: In lymphocytes, only in NLVH-adult group we observed drd2 mRNA expression, while drd2 mRNA
expression was not observed in the NLVH-juvenile rats; on the other hand, the drd3 mRNA expression did not show
significant statistical differences. In hippocampus no differences were observed between drd2 mRNA or drd3 mRNA
expression when comparing juvenile/adult shams with NLVH groups. In the prefrontal area, a decrease in drd2
mRNA expression levels were observed in the NLVH-adult group (F(1,3) = 52.83, p = 0,005) in comparison to the
sham-adult group. Finally, in the nucleus accumbens, a strong decrease of drd3 mRNA expression was observed in
the NLVH-adult group in comparison to the sham-adult group (F(1,3) = 123,2, p < 0.001).
Conclusions: Our results show that differences in drd2 and drd3 mRNA levels in NLVH-adults are patent when
compared to the sham-adult group or with the NLVH-juvenile group. These findings suggest that the expression
levels may be regulated during adulthood, leading to behavioral and neurochemical changes related to
schizophrenia. Therefore, more studies are necessary to determine the role of dopamine receptors as possible
molecular markers for neurodevelopmental changes associated with schizophrenia.
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Schizophrenia is a mental illness which causes a heavy
economic burden to society; it affects 1 % of the world
population, and it usually develops during the reproduct-
ive stage of the person and remains present throughout
his/her life [1, 2]. The difficulties to obtain adequate hu-
man brain-samples and the increasing necessity to study
schizophrenia have led to the development of several
animal models. These animal models can be divided into
three categories: pharmacological models, genetic
models (induced genetic mutations or deletions) and
neurodevelopmental models (induced by a natural or
neurotoxic injury or by environmental factors during
neurodevelopment) [3–5].
The neonatal lesion in the ventral hippocampus
(NLVH) model in animals is based on a neurodeve-
lopmental hypothesis implicating that at an early age
(probably during the prenatal stage) fundamental al-
terations may induce the occurrence of schizophrenia
[6–8]. For instance, Tseng et al. (2009) suggest that
NLVH disrupts the dorso-lateral cortical morphogen-
esis, since these authors observed that the dopamin-
ergic pathway sets off from the ventral hippocampus
to the dorso-lateral area in rat embryos [9]. This ef-
fect is more evident in young rats whereas during
adolescence rats lose the drd2 modulation in cortical
interneurons, as well as the onset of cortical matur-
ation [10]. These findings increase the possibility that
maturation of local inhibitory circuits within the PFC
may be caused by NLVH [11]. In mental diseases,
particularly those treated with antipsychotic medica-
tion (including schizophrenia), dopaminergic receptors
are of particular interest [3, 4]. The gene expression
of dopamine receptors has been directly studied in
the brain, and it has also been monitored in other
cell populations such as lymphocytes [12]. Therefore,
peripheral dopamine receptors may serve as represen-
tative markers for changes occurring within the cen-
tral nervous system associated with neuropsychiatric
syndromes such as depression and schizophrenia [13].
There are various hypotheses trying to explain the
impairment in dopamine transmission [14]. This
monoamine dysfunction may be due to immune-
inflammatory or neuroendocrine causes or to neuro-
plasticity malfunctioning [15]. Some authors ascertain
that dopamine can directly affect the immune system.
They suggest that further research on animal models
must address not only the effects of dopaminergic
substances on peripheral expression of dopamine re-
ceptors, but also the correlation between the regula-
tion of central and peripheral dopamine receptors [16,
17]. To explore this possibility the present study com-
pares mRNA expression of dopamine receptors (drd2




The cohort of animals in this report is the same used in a
previous study [18]. Twenty male Wistar rats were used in
this study; all animals came from pregnant rats in our la-
boratory. They were individually housed in breeding cages
under a 12-h light/12-h dark cycle. The sample was di-
vided into four groups: 1) NLVH-juvenile group, 2) sham-
juvenile group, 3) NLVH-adult group and 4) sham-adult
group. Each group was housed in a cage and kept under
an inverted 12-h light/12-h dark cycle (lights off at
10:00 a.m.) and controlled temperature (22.2 °C). Testing
was routinely performed between 10:00 a.m. and
3:00 p.m.; animals had free access to food and water
throughout the experiment [5]. The local committee of
ethics on animal experimentation approved the experi-
mental procedures, which complied with the regulations
established in the Mexican official norm for the use and
care of laboratory animals, “NOM-062-ZOO-1999”, as
well as the regulations of the Ethics Committee of the
International Association for the Study of Pain [19].
Neonatal ventral hippocampus lesion
Bilateral NLVH was performed in neonatal specimens as
described by Lipska et al. [20]. Litters of four to eight
male pups were grouped and submitted to surgical alter-
ation on postnatal days five to seven (PD 5–7) (weight
10–13 g). Pups were randomly assigned to lesion or
sham status and anesthetized with hypothermia by pla-
cing the animals on ice for 10–15 min. Pups were then
taped to a platform fixed to a stereotaxic Kopf instru-
ment and skin incisions overlying the skull were made.
Bilateral ventral hippocampus lesions were performed by
infusing 0.15 μl/min (over a period of 2 min) of ibotenic
acid (Sigma, St Louis, MO, USA) (lesion) or PBS solu-
tion (for the sham groups) through a Hamilton needle in
the following coordinates relative to Bregma: anterior-
posterior (AP) -2.0; medium lateral (ML) ±2.5, and
dorsum-ventral (DV) -3.3 in relation to Bregma [21].
We had successfully established the rat NLVH model as
reported elsewhere [18].
RNA extraction
The animals were sacrificed by rapid decapitation at 45
and 95 days old. Following this procedure, their brains
were dissected and the following regions were selected:
prefrontal cortex, nucleus accumbens and hippocampus.
Trunk blood was collected and lymphocytes were iso-
lated by differential centrifugation using a Ficoll density
gradient centrifugation and stored at −70 °C until use.
Subsequently, RNA extraction for each brain region was
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gies) according to the manufacturer’s instructions. The
RNA obtained was quantified by plaque fluorometry
utilizing fluorescent dyes to determine the concentration
of nucleic acids in a simple using the Quant-IT Ribo-
Green RNA assay (Invitrogen) according to the manu-
facturer’s instructions, as well as a Fluoroskan Ascent
equipment (Thermo Electron Corporation, Vantaa,
Finland). The cDNA was synthesized using Super Script
III First-Strand Synthesis Supermix (Invitrogen) accord-
ing to the manufacturer’s instructions. The quantifica-
tion of drd2 and drd3 expression was performed
through TaqMan Gene Expression Assays using the Ap-
plied Biosystems 7900HT Fast Real-Time PCR Systems.
Relative expression was evaluated through 18S rRNA
gene as the endogenous control. The comparative CT
method (2ΔΔCT) was used to calculate drd2 and drd3
expression levels in the brain samples and lymphocytes.drd2 and drd3 expression assays
Gene expression of drd2 and drd3 was determined by real
time PCR, running the cDNA reactions mixtures on a
4900 Real Time PCR System (Applied Biosystems). The
initial cDNA quantity was 25 ng, although increasing con-
centrations were also used (50, 100 and 200 ng). We uti-
lized TaqMan® rat probes drd2-10 FAM (Rn00561126-m1)
and drd3 FAM (Rn00691132-m1) (Applied Biosystems),
in multiple assays (by triplicate), using ribosomal RNA as
endogenous gene (TaqMan Ribosomal RNA Control Re-
agents VIC® dye; Applied Biosystems). Data were analyzed
with the CT comparative method (2ΔΔCT). All the experi-
ments were run in triplicate. Ventral hippocampus lesionsFig. 1 drd2 and drd3 gene expression in lymphocytes of juvenile and adultwere verified by means of histological stained sections for
both juvenile and adult stages.Statistical analysis
Data are presented as mean ± SEM. For each region:
lymphocytes, hippocampus, prefrontal area and nucleus
accumbens a Two-Way ANOVAs was performed to
compare the sham and the NLVH groups. To compare
juveniles against adults, a two-way ANOVA was per-
formed followed by Bonferroni test for post hoc. The
level of statistical significance was established at p < 0.05.Results
drd2 and drd3 mRNA expression levels in lymphocytes of
juvenile and adult groups
Gene expression and quantification of drd2 mRNA in lym-
phocytes were higher in NLVH-adult rats than in the
sham-adults (where no drd2 mRNA expression was ob-
served). This means that the expression of this marker was
only present when the lesion procedure was performed
(Fig. 1). In the sham-adult group, only the endogenous ex-
pression of the 18S rRNA gene was detected. In the juvenile
group no expression was observed. In consequence, the ex-
pression of the drd2 mRNA in the NLVH-group adults
showed major expression that in NLVH-juvenile groups.
In contrast, drd3 mRNA expression levels were ob-
served in both groups. However, no differences were ob-
served when comparing the drd3 mRNA expression
between sham-adults and NLVH-adults (F (1,4) =3.85, p
= 0.12) (Fig. 1). Equally, no differences were observed
between the juvenile groups (F (1,4) =4.15, p = 0.38).
However, the expression of drd3 mRNA in the sham-groups. ***p < 0.001
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(mean diff. -6.62 CI diff:-9.01- -4.24, p < 0.05). Equally
the expression of NLVH-adults showed higher expres-
sion than the NLVH-juvenile group (mean diff. -7.51 CI
diff:-9.87- -5.12, p < 0.05).drd2 and drd3 mRNA expression levels in the
hippocampus of juvenile and adult groups
The drd2 mRNA expression levels (F (3,13) = 3.93, p =
0.06) in the hippocampus comparing NLVH-adults
and sham-adults were no different (F (1,4) = 3.76, p =
0.12); likewise, the comparison between NLVH-
juveniles and sham-juveniles showed no difference of
drd2 mRNA expression levels (F (1,4) = 3.29, p = 0.14).
When we compared the expression of drd2 mRNA be-
tween sham-adults and sham-juveniles not statistical
differences were observed (mean diff. -3.05 CI diff:-
6.69- 0.59, p > 0.05), or when comparing NLVH-adults
and NLV-juveniles (mean diff. 1.60 CI diff:-2.04- 5.24,
p > 0.05).
In addition, no differences of the drd3 mRNA ex-
pression levels were found between sham-adults and
NLVH-adults (F (1,4) = 5.72, p = 0.07) (Fig. 2). Simi-
larly, no differences in drd3 mRNA expression levels
were observed between sham-juveniles and NLVH-
juveniles (F (1,4) = 1.11, p = 0,33). The expression of
drd3 mRNA in the sham-adult group showed no stat-
istical difference when compared with the sham-
juvenile group (mean diff. -3.50 CI diff:-6.69- 0.59,
p > 0.05); equally, the comparison between NLVH-
juvenile and NLVH-adults showed no difference of
drd3 mRNA expression (mean diff. 1.60 CI diff:-2.04-
5.24, p > 0.05).Fig. 2 drd2 and drd3 gene expression in the hippocampus of juvenile anddrd2 and drd3 mRNA expression levels in prefrontal area
of juvenile and adult groups
In the prefrontal cortex (Fig. 3), a difference was observed
when comparing the adults, as the sham group showed
higher levels of drd2 mRNA expression than the NLVH
group (F(1,3) = 52.83, p = 0.005). However, no differences of
drd2 mRNA expression levels were observed in sham-
juveniles when compared with the NLVH-juveniles (F(1,3)
= 5,5, p = 0.1). When a comparison between juvenile and
adult groups was performed, we did not observe differences
between the NLVH groups (mean diff. 6.53 CI diff:-1.12-
-14.19, p > 0.05) or between the sham groups (mean diff.
2.64 CI diff:-4.96 – 10.35, p > 0.05).
Regarding the drd3 mRNA expression levels, no differ-
ences were observed between the sham-adults and
NLVH-adults (F (1,3) = 2.30, p = 0.22). Similarly, no dif-
ferences in drd3 mRNA expression levels were observed
between sham-juveniles and NLVH-juveniles (F (1,3) =
1.51, p = 0.30) (Fig. 3). In addition, no differences of the
drd3 mRNA expression levels were found between the
NLVH-juveniles and NLVH-adults (mean diff. 7.19 CI
diff:-19.01 – 4.61, p > 0.05) (Fig. 3). Also, no differences
of the drd3 mRNA expression levels were observed be-
tween sham-juveniles and sham-adults (mean diff. -4.75
CI diff:-16.56 – 7.06, p > 0.05).drd2 and drd3 mRNA expression levels in the nucleus
accumbens of juvenile and adult groups
With respect to the nucleus accumbens, when the expres-
sion levels of drd2 mRNA were evaluated in NLVH-adults,
no difference was observed when compared with the sham-
adults (F (1,3) =5,5, p = 0.1). Similarly, no statistical differ-
ences were observed when the sham-juveniles and NLVH-adult groups. Two-Way ANOVAs test
Fig. 3 drd2 and drd3 gene expression in prefrontal cortex of juvenile and adult groups. Two-Way ANOVAs test. ***p < 0.001
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in the NLVH-adult group a marked decrease of the drd2
expression levels was detected in comparison with the
NLVH-juvenile group (mean diff. 12.09 CI diff:7.68 – 16.50,
p < 0.05); equally, the expression in the sham-adult group
was smaller than in the sham-juvenile group (mean diff.
11.87 CI diff:7.46 – 16.28, p < 0.05) (Fig. 4).
When the drd3 mRNA expression levels were evaluated
in adults, a marked decrease of drd3 mRNA was observed
in NLVH-adults when compared with sham-adults (F (1,3)
= 123.2, p < 0.001) (Fig. 4). Between the juvenile groups no
differences were observed (F (1,3) = 0.074, p = 0.45). Finally,
the expression of drd3 mRNA in the sham-adult group wasFig. 4 drd2 and drd3 gene expression in nucleus accumbens of juvenile anhigher than in the sham-juvenile group (mean diff. -5.25, p
< 0.05); whereas the comparison between NLVH-juveniles
and NLVH-adults showed a lower expression of drd3 in the
adult group (mean diff. 12.48, p < 0.01).
Discussion
The present study provides important evidence about
the role of drd2 and drd3 genes in lymphocytes and in
some brain areas (hippocampus, prefrontal cortex and
nucleus accumbens) in NLVH rats at two different age
periods: young and adult. Our study showed that the
drd3 mRNA expression levels in lymphocytes were de-
tected from postnatal day 45. In contrast, drd2d adult groups. Two-Way ANOVAs test. p < 0.001
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(90 days of age); which may indicate late neurodevelop-
mental effects. In rats, synaptic pruning in drd1 and
drd2 receptors occurs during the peri-adolescent period
(postnatal days 42–44). It has been described that after
this pruning, the onset of schizophrenia commonly oc-
curs [22, 23]. In the juvenile stage no expression changes
were found in any of the tissues studied. Previously,
Flores and colleagues conducted a study of dopamine re-
ceptors expression using the NLHV model and autoradi-
ography at 41 days of age and found no changes in the
expression of drd1, drd2 and drd3 receptors [24]. El-
Rawas et al. also evaluated drd2 expression by immuno-
histochemistry in several brain regions and only encoun-
tered changes in the putamen [25]. In our evaluation,
only changes in adult rats were detected (Figs. 1, 3 and
4). These findings suggest that the expression levels of
some dopamine receptors are regulated during adult-
hood, leading to behavioral and neurochemical changes
related to schizophrenia.
Regarding the group of NLHV-adult rats, a decreasing
trend for drd3 and a clear decrease in drd2 mRNA ex-
pression was observed in the prefrontal cortex compared
to sham-adults (Fig. 3). Flores et al. used autoradiog-
raphy and reported no changes in expression observed
in this molecule in animals at 62 days of age [24, 26].
Possibly, the drd2 expression may be observed at later
ages, since we detected these differences only after
90 days. The regulation of drd2 expression in the pre-
frontal cortex of the adult rats group may indicate late
neurodevelopmental effects. Cognitive deficits in
humans have been correlated with an imbalance of D1
and D2 receptors in the prefrontal cortex [27, 28]. The
prefrontal cortex, hippocampus and the developmentally
dependent synaptic pruning in the juvenile stage may
contribute to the present results [22]. In rats, neuronal
pruning of drd1 and drd2 receptors occurs during the
peri-adolescent period (42–44 days). In humans, after
this pruning takes place, it is possible to observe the
symptoms of schizophrenia [22, 23]. Furthermore, the
development of the prefrontal cortex in the early gesta-
tion stage and in adolescence represent two critical pe-
riods of vulnerability for schizophrenia in humans [29].
In the case of the mRNA expression in the hippocampus,
no changes were observed for drd2 or drd3. However, with
regard to the accumbens core, a clear decrease in the drd2
transcript was observed in adults against juveniles (Fig. 4),
possibly due to neuronal pruning, since the dopamine hy-
pothesis suggests a disturbed and hyperactive dopaminergic
signal transduction; the evidence indicates that dopamine
receptors are produced in excess before puberty (day 40).
Moreover, Teicher et al. reported that at 40 days of age
there is a slight decrease in drd2 receptors in the nucleus
accumbens [22]. Also, a decrease of thedrd3 expression wasobserved in the NLVH-adults, as reported by Flores et al.
when they analyzed rats at 63 days of age using autoradiog-
raphy [24]. Several reports of reduced drd3 mRNA in
schizophrenic brains further support the potential implica-
tion of this receptor subtype in this disorder [30, 31].
We consider that when our rats reached adulthood, the
drd2 was expressed only as a response to the lesion per-
formed when neonates. In addition, we observed a reduc-
tion of the drd2 expression in the prefrontal cortex in
NLVH-adult rats. Conversely, in lymphocytes we encoun-
tered high drd2 expression levels also in NLVH-adults.
These preliminary results appear contradictory, which may
indicate that blood changes do not reflect brain changes in
the expression of the message for this receptor. Therefore,
it is important to further investigate expression profiles in
other brain areas represented in schizophrenia. On the
other hand, it was not possible to detect drd2 expression in
the sham groups; this is consistent with other reports,
which indicates that although all five dopaminergic recep-
tors are present in lymphocytes of peripheral blood, the
drd2 expression is not observed in healthy animals without
NLVH manipulation (sham groups) [16]. Therefore, drd2
expression may be directly related to NLVH in this study.
To date, there are few reports on dopaminergic receptors
using the NLVH model. Using microarray technology, drd2
over-expression has been observed in patients; hence this
dopamine receptor has been proposed as a peripheral blood
biomarker [32, 33]. Another study showed that drd2
mRNA levels in lymphocytes of peripheral blood were
correlated with positive symptoms in acute schizophrenia
patients [34]. The analysis of dopamine receptors in lym-
phocytes of peripheral blood could be a useful tool for
assessing the properties of dopaminergic function in psy-
chopathological traits of schizophrenia [35, 36]. Finally, fur-
ther studies that allow the analysis of behavioral alterations
in rats are needed to confirm the findings of this study.
Conclusions
We encountered significant differences in the effect of
NLVH on drd2 and drd3 mRNA expression levels
among the brain regions analyzed in rat adulthood.
These findings suggest that expression levels of some
dopamine receptors may be regulated during adulthood,
leading to behavioral and neurochemical changes associ-
ated with schizophrenia. However, more studies are ne-
cessary to establish whether changes in drd2 mRNA
expression levels could represent a molecular marker for
neurodevelopmental changes related to schizophrenia.
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